Deals

Cowen Places $10M Tranzyme Registered Direct

By |

Tranzyme (TZYM) announced that it has raised $10 million in an underwritten Registered Direct transaction. The common stock was sold at $3.85 per share, an approximate 10% discount to the market price ($4.27) of TZYM at deal announcement. Cowen and Company acted as Lead Agent with JMP Securities acting as Co-Agent on the transaction. Placement Agent counsel was LeClairRyan, and issuer counsels were Goodwin Procter and Norton Rose Canada. The transaction is expected to close on September 18, 2012.

Deals

GlaxoSmithKline Buys into Response Genetics at 22% Premium

By |

Response Genetics (RGDX) announced that it has raised $8.8 million in a Common Stock transaction. The common stock was sold at $1.10 per share, an approximate 22% premium to the market price ($0.90) of RGDX at deal announcement. The investors were GlaxoSmithKline and an existing shareholder. The transaction closed on Sept. 13, 2012.

Deals

Pluristem Therapeutics Raises $32M in 14th EPP

By |

Pluristem Therapeutics (PSTI) announced that it has raised $32 million in a CMPO/Overnight transaction. The common stock was sold at $4.00 per share, an approximate 12% discount to the market price ($4.54) of PSTI at deal announcement. A series of 2,800,000 60-Month Warrants with an exercise price of $5.00 per share (10.13% premium) was issued to the investors in this transaction. Jefferies & Company acted as Lead Agent with Oppenheimer, Maxim Group, and Needham & Company acting as Co-Agents. Leader Capital Markets acted as Financial Advisor for the Company. The Placement Agent counsel was Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, and the issuer counsels were Sullivan & Worcester and Zysman, Aharoni, Gayer & Company Law Offices.

Deals

Opexa Therapeutics in ATM with Brinson Patrick

By |

Cellular therapy developer Opexa Therapeutics (OPXA) announced that it has secured up to $2.6 million in an ATM (At the Market) transaction with Brinson Patrick Securities. The purchase price is the prevailing market price at the time of the Draw Down Notice. Issuer counsel was Pillsbury, Winthrop, Shaw & Pittman. This is Opexa's tenth PIPE since 2004, according to PlacementTracker data indicating that the company was formerly known as PharmaFrontiers Corp. prior to 2008.